Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study

Next Previous
Trial Profile

A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lasmiditan (Primary)
  • Indications Migraine; Migraine with aura; Migraine without aura
  • Focus Registrational; Therapeutic Use
  • Acronyms SAMURAI
  • Sponsors CoLucid Pharmaceuticals; Eli Lilly and Company

    • Most Recent Events

    • 02 Jul 2022 Results of four pooled analysis from (NCT02439320, NCT02605174, NCT03962738, NCT03670810) published in the CNS Drugs
    • 01 May 2022 Results of post-hoc pooled analysis of two studies (SAMURAI [NCT02439320] and SPARTAN [NCT02605174]) assessing details migraine disease characteristics and treatment outcomes after treatment with lasmiditan, published in the Current Medical Research and Opinion.
    • 26 Apr 2022 Results of post-hoc analysis of 4 studies (AMURAI, SPARTAN, CENTURION, and MONONOFU) assessing the efficacy and safety of lasmiditan in patients with and without at least one triptan contraindication, published in the Pain and Therapy.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top